Affordable Access

Publisher Website

Comparison of lifibrol to other lipid-regulating agents in experimental animals

Authors
Journal
Pharmacological Research
1043-6618
Publisher
Elsevier
Publication Date
Volume
29
Issue
4
Identifiers
DOI: 10.1016/1043-6618(94)80056-1
Keywords
  • Cholesterol
  • Hmg-Coa Reductase
  • Fibrates
  • Hypolipidemic
  • Triglycerides
  • Rat
Disciplines
  • Biology

Abstract

Abstract In vitro data suggests that lifibrol lowers plasma cholesterol by inhibiting cholesterol synthesis. We report that lifibrol is far less potent in vitro and in vivo than lovastatin for inhibiting 14C-acetate incorporation into sterols. Moreover, several major differences between lifobrol and lovastatin were noted in various animal models. In contrast, lifibrol exhibited several activities in common with gemfibrozil, another phenoxy-acid-type drug. Specifically, in normal rats lifibrol, like gemfibrozil, lowered plasma non- HDL-cholesterol and triglycerides, and increased liver weight and hepatic peroxisomal marker enzyme activities. Lovastatin only lowered plasma triglycerides. In cholesterol-fed rats lifibrol and gemfibrozil lowered non-HDL-cholesterol and elevated HDL-cholesterol while lovastatin was inactive. Finally, lovastatin but not lifibrol exhibited hypocholesterolemic activity in normal guinea pigs and resin-primed dogs. Our interpretation is that these data do not support the notion that lifibrol lowers plasma cholesterol in vivo by inhibiting cholesterol synthesis.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

The lipotropic agents in the protection of the liv...

on Proceedings of the Royal Socie... May 29, 1956

Comparison of the cardiovascular actions of ORG NC...

on BJA British Journal of Anaesth... 1980

A comparison of the technetium-labeled myocardial...

on International Journal of Nucle... Jan 01, 1984
More articles like this..